Standout Papers

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report... 2019 2026 2021 2023 371
  1. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study (2019)
    Funda Meric‐Bernstam, Herbert I. Hurwitz et al. The Lancet Oncology

Citation Impact

1 by Nobel laureates 3 from Science/Nature 72 standout
Sub-graph 1 of 22

Citing Papers

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
26 intermediate papers

Works of Steven Blotner being referenced

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
2021
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
2019 Standout
and 11 more

Author Peers

Author Oncology Infectious Diseases Molecular Biology PRM Last Decade Papers Cites
Steven Blotner 585 46 253 221 36 1.1k
Marion Blute 17 31 985
Chester R. Lapeza 17 38 7 25 1.2k
Peter Handke 63 108
Qin Liu 59 1 209 15 11 268
A. Jamali 5 7 14 564

All Works

Loading papers...

Rankless by CCL
2026